Cell Therapy News Volume 21.36 | Oct 19 2020

May 12, 2022

CTN 21.36 | Oct 19 2020

Cell Therapy News by STEMCELL Technologies

Vol. 21.36 – 19 October, 2020

TOP STORY

Microglia-Organized Scar-Free Spinal Cord Repair in Neonatal Mice

Scientists transplanted either neonatal microglia or adult microglia treated with peptidase inhibitors into spinal cord lesions of adult mice, and found that both types of microglia significantly improved healing and axon regrowth.
[Nature]

Abstract

Start Fast. Finish Faster. Streamline your assays with purified human primary cells from STEMCELL Technologies. View products now.

PUBLICATIONSRanked by the impact factor of the journal

Anti-GD2
CAR-NKT Cells in Patients with Relapsed or Refractory Neuroblastoma: An Interim Analysis

Investigators report interim results from all three patients enrolled on dose level 1 in a Phase I dose-escalation trial of autologous natural killer T cells engineered to co-express a GD2-specific chimeric antigen receptor with interleukin-15 in children with relapsed or resistant neuroblastoma.
[Nature Medicine]

Abstract

Systemic
Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid

Scientists evaluated pembrolizumab concentrations and PD-1 blockade on T cells in the cerebrospinal fluid after intravenous administration. Cerebrospinal fluid and blood samples were collected from ten adult patients with high-grade gliomas who were participating in clinical trials of intracranially administered chimeric antigen receptor T cells and intravenous pembrolizumab.
[JAMA Oncology]

Full Article

Transplantation
of hPSC-Derived Pericyte-Like Cells Promotes Functional Recovery in Ischemic Stroke Mice

The authors generated pericyte-like cells (PCs) from human (h)PSCs through the intermediate stage of the cranial neural crest (CNC) and revealed that the hPSC-CNC PCs expressed typical pericyte markers including PDGFRβ, CD146, NG2, CD13, Caldesmon, and Vimentin, and displayed distinct contractile properties, vasculogenic potential and endothelial barrier function.
[Nature Communications]

Full Article

In Vivo
CRISPR/Cas9 Targeting of Fusion Oncogenes for Selective Elimination of Cancer Cells

Investigators devised a simple, efficient and non-patient-specific gene-editing strategy through targeting of two introns of the genes involved in the rearrangement, allowing for robust disruption of the fusion oncogenes specifically in cancer cells.
[Nature Communications]

Full Article Press Release

Human
Cerebral Organoids Establish Subcortical Projections in the Mouse Brain after Transplantation

Researchers optimized a culturing protocol capable of efficiently generating small human cerebral organoids derived from hESCs and hiPSCs.
[Molecular Psychiatry]

Full Article

CD19-Specific
CAR-T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor is Effective in Patients with PD-L1 Positive B-Cell Lymphoma

Scientists generated a novel anti-CD19 CAR expressing PD-1/CD28 chimeric switch-receptor. They then conducted a Phase Ib study to evaluate safety and efficacy of CD19-PD-1/CD28-CAR T cells in the treatment of PD-L1+ B-cell lymphoma.
[Clinical Cancer Research]

Abstract

Treatment
of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity

The authors developed a ‘dual-CAR’ targeting two multiple myeloma-associated antigens and explored its safety and efficacy. To reduce the “off target” toxicity, they used the recognition of paired antigens that were co-expressed by the tumor, to induce efficient CAR T cell activation.
[Cancer Immunology Research]

Abstract

Donor-Derived
CD19 CAR-T Cell Therapy of Relapse of CD19-Positive B-ALL Post Allotransplant

43 subjects with B-cell acute lymphoblastic leukemia relapsing post allotransplant received CAR-T cells were analyzed.
[Leukemia]

Full Article

Melphalan
and Exportin 1 Inhibitors Exert Synergistic Anti-Tumor Effects in Preclinical Models of Human Multiple Myeloma

Multiple myeloma (MM) cells from newly diagnosed and relapsed/refractory MM patients were also sensitized by XPO1i to melphalan. In NOD/SCID-γ mice challenged with either parental 8226 or U266 MM and melphalan-resistant MM tumors, XPO1i/melphalan combination treatments demonstrated stronger synergistic anti-tumor effects than single-agent melphalan with minimal toxicity.
[Cancer Research]

Abstract

Multiscale
Fluorescent Tracking of Immune Cells in the Liver with a Highly Biocompatible Far-Red Emitting Polymer Probe

A newly-designed water-soluble far-red emitting polymer probe, 19K-6H, with a large Stokes shift, was thus evaluated for the tracking of primary immune CD8 T cells. 19K-6H-labelled primary CD8 T cells were injected to mice in a classical model of immune mediated hepatitis.
[Scientific Reports]

Full Article

Engineered
AAV8 Capsid Acquires Heparin and AVB Sepharose Binding Capacity but Has Altered In Vivo Transduction Efficiency

In vivo comparison by intramuscular, intravenous, and intraperitoneal vector administration demonstrated a significant decrease in adeno-associated virus 8-AVB-heparan sulfate transduction efficiency without alteration of the transduction profile.
[Gene Therapy]

Abstract

Request your free copy of the 'Production of Chimeric Antigen Receptor T Cells' Wallchart

REVIEWS

Overview of Current Targeted Therapy in Gallbladder Cancer

The authors primarily focus on the targeted therapy capable of specifically inhibiting individual key molecules that govern aberrant signaling cascades in gallbladder cancer (GBC). Global clinical trials of targeted therapy in GBC are updated and may offer great value for novel pathologic and therapeutic insights of this deadly disease, ultimately improving the efficacy of treatment.
[Signal Transduction and Targeted Therapy]

Full Article

Gene
Therapy and Gene Correction: Targets, Progress, and Challenges for Treating Human Diseases

Gene correction using CRISPR-Cas9 is an extension of gene therapy that has received considerable attention in recent years and boasts many possible uses beyond classical gene therapy approaches.
[Gene Therapy]

Abstract

INDUSTRY AND POLICY NEWS

XenoTherapeutics Granted US Patent Covering Method of Producing Clinically Acceptable Porcine Cells, Tissues, and Organs for Human Xenotransplantation

XenoTherapeutics announced that the US Patent and Trademark Office has granted US Patent No. 10,799,614 to XenoTherapeutics, the patent covering methods for producing live-cell biological products from source animal donors for human xenotransplantation.
[XenoTherapeutics (GlobeNewswire, Inc.)]

Press Release

Allogene
Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Advancement of Allogeneic CAR T Therapy (AlloCAR T^™)

Allogene Therapeutics, Inc. and the University of Texas MD Anderson Cancer Center announced a strategic five-year collaboration agreement for the preclinical and clinical investigation of AlloCAR T candidates across Allogene’s broad portfolio of hematologic and solid tumors.
[Allogene Therapeutics, Inc.]

Press Release

Precision BioSciences Announces US Patent Trial and Appeal Board Upholds Allogeneic CAR T Patents

Precision BioSciences, Inc. announced that the US Patent and Trademark Office’s Patent Trial and Appeal Board has ruled in favor of Precision BioSciences in two patent interference proceedings that challenged nine US patents owned by Precision.
[Precision BioSciences, Inc.]

Press Release

FEATURED EVENT

Microglia-Organized Scar-Free Spinal Cord Repair in Neonatal Mice

Anti-GD2
CAR-NKT Cells in Patients with Relapsed or Refractory Neuroblastoma: An Interim Analysis

Systemic
Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid

Transplantation
of hPSC-Derived Pericyte-Like Cells Promotes Functional Recovery in Ischemic Stroke Mice

In Vivo
CRISPR/Cas9 Targeting of Fusion Oncogenes for Selective Elimination of Cancer Cells

Human
Cerebral Organoids Establish Subcortical Projections in the Mouse Brain after Transplantation

CD19-Specific
CAR-T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor is Effective in Patients with PD-L1 Positive B-Cell Lymphoma

Treatment
of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity

Donor-Derived
CD19 CAR-T Cell Therapy of Relapse of CD19-Positive B-ALL Post Allotransplant

Melphalan
and Exportin 1 Inhibitors Exert Synergistic Anti-Tumor Effects in Preclinical Models of Human Multiple Myeloma

Multiscale
Fluorescent Tracking of Immune Cells in the Liver with a Highly Biocompatible Far-Red Emitting Polymer Probe

Engineered
AAV8 Capsid Acquires Heparin and AVB Sepharose Binding Capacity but Has Altered In Vivo Transduction Efficiency

Overview of Current Targeted Therapy in Gallbladder Cancer

Gene
Therapy and Gene Correction: Targets, Progress, and Challenges for Treating Human Diseases

XenoTherapeutics Granted US Patent Covering Method of Producing Clinically Acceptable Porcine Cells, Tissues, and Organs for Human Xenotransplantation

Allogene
Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Advancement of Allogeneic CAR T Therapy (AlloCAR T^™)

Precision BioSciences Announces US Patent Trial and Appeal Board Upholds Allogeneic CAR T Patents

Keystone
Symposia: Emerging Cell Therapies: Realizing the Vision of NextGen Cell Therapeutics

> See All Events

Postdoctoral Fellow – Cancer Immunology and Immunotherapy

Postdoctoral Researcher – Translational Neuroscience

Research
Positions – Cancer and Immunotherapy

Vice
President – Oncology and Cell Therapy

Research
Fellow Position – Neural Cell Therapy

> See All Jobs